Diversified Trust Co boosted its position in Morgan Stanley by 63.9% during the third quarter, adding 18,800 shares to reach a total holding of 48,243 shares, valued at $7.67 million on the latest SEC filing. Vanguard Group Inc. increased its stake by 1.1% in the second quarter, acquiring 1.35 million additional shares for a total of 119.12 million shares, representing $16.78 billion in assets. Fisher Asset Management added 749,150 shares in the same period, bringing its total to 24.05 million shares worth $3.39 billion. New positions and boosts were also reported from Norges Bank ($2.23 billion), Ameriprise Financial (13.44 million shares), and Charles Schwab Investment Management (10.98 million shares), driving institutional ownership to 84.19%.

In its latest quarter, Morgan Stanley generated revenue of $17.98 billion, surpassing consensus forecasts by $1.56 billion and marking an 18.5% year-over-year increase. Adjusted earnings per share reached $2.80, beating estimates by $0.73. Return on equity stood at 16.40%, with a net profit margin of 13.85%. The firm’s debt-to-equity ratio remains at 3.27, while its quick and current ratios both sit at 0.79, reflecting a balanced liquidity position. Analysts now expect full-year EPS of $8.56, underscoring confidence in sustained momentum across Institutional Securities, Wealth Management and Investment Management segments.

The board declared a quarterly dividend of $1.00 per share, payable to shareholders of record on October 31, with payment made on November 14. This distribution annualizes to $4.00 per share, yielding 2.2% based on current valuations, and reflects a payout ratio of 41.03%. This marks the third consecutive year of dividend growth and underscores the firm’s commitment to returning capital to investors alongside reinvestment in growth initiatives.

CEO James Gorman reduced his personal stake by selling 100,000 shares at an average price of $164.34, resulting in proceeds of $16.43 million and leaving him with 574,986 shares. Corporate insiders now hold 0.19% of outstanding shares. On the research front, Keefe, Bruyette & Woods raised its target from $184 to $202 with an Outperform rating; Wolfe Research upgraded the stock to Outperform with a $198 target; UBS and JPMorgan both maintained Neutral ratings but lifted targets to $165 and $157, respectively; DBS Bank initiated coverage with a Moderate Buy. Consensus among 18 analysts reflects a Moderate Buy stance and an average price target near $175.